Free tool
FAERS Monitor: Vyzulta
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 207795 or its brand name (Vyzulta, Latanoprostene Bunod). Reports on generic versions are filed under their own applications.
Reports
1,146
Serious
423
37% of reports
Hospitalization
119
Death reported
56
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- eye pain120
- eye irritation110
- ocular hyperaemia81
- intraocular pressure increased63
- drug ineffective61
- off label use54
- vision blurred49
- death45
- fatigue43
- headache43
- visual impairment42
- product quality issue39
- pain38
- product dose omission issue37
- dizziness35
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2015 | 1 |
| 2016 | 1 |
| 2018 | 110 |
| 2019 | 76 |
| 2020 | 94 |
| 2021 | 100 |
| 2022 | 106 |
| 2023 | 154 |
| 2024 | 165 |
| 2025 | 158 |
| 2026 | 181 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,013 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| intraocular pressure increasedSignal | 63 | 90.9 | 71.5 | 5,489 |
| eye painSignal | 120 | 39.1 | 33.0 | 4,422 |
| eye irritationSignal | 110 | 35.1 | 29.4 | 3,618 |
| ocular hyperaemiaSignal | 81 | 31.4 | 25.4 | 2,353 |
| vision blurredSignal | 49 | 6.6 | 5.0 | 226 |
| visual impairmentSignal | 42 | 6.2 | 4.6 | 180 |
| product quality issueSignal | 39 | 5.3 | 3.9 | 132 |
| product dose omission issueSignal | 37 | 2.3 | 1.7 | 27 |
| dizziness | 35 | 1.3 | 0.9 | 2 |
| headache | 43 | 1.3 | 0.9 | 2 |
| pain | 38 | 1.1 | 0.8 | 1 |
| off label use | 54 | 1.1 | 0.9 | 1 |
| fatigue | 43 | 1.0 | 0.8 | 0 |
| death | 45 | 1.0 | 0.7 | 0 |
| drug ineffective | 61 | 0.8 | 0.7 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.